p21 Is Necessary for the p53-mediated G1 Arrest in Human Cancer Cells

Cancer Research

Volumn 55, Issue 22, 1995, Pages 5187-5190

  Waldman, Todd ^a   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0028849274     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
2. Harper, J. W., Adami, G. R., Wei, N., Kayomarsl, K., and Elledge, S. J. The p21 cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases. Cell, 75: 805-816, 1993.
3. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
4. Gu, Y., Turek, C. W., and Morgan, D. O. Inactivation of cdk2 activity in vivo by an associated 20K regulatory subunit. Nature (Lond.), 366: 707-710, 1993.
5. Noda, A., Ning, Y., Vanable, S. F., Pereira-Smith, O. M., and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 90-98, 1994.
6. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
7. Elledge, S. J., and Harper, J. W. Cdk inhibitors on the threshold of checkpoints and development. Curr. Opin. Cell Biol., 6: 847-852, 1994.
8. Hunter, T., and Pines, J. Cyclins and cancer. II. Cyclin D and cdk inhibitors come of age. Cell, 79: 573-582, 1994.
9. Sherr, C. J., and Roberts, J. M. Inhibitors of mammalian Gl cyclin-dependent kinases. Genes & Dev., 9: 1149-1163, 1995.
10. Deng, C., Zhang, P., Harper, J. W., Elledge, S. J., and Leder, P. Mice lacking p2iCiPi/wafi un(jerg0 normal development, but are defective in Gl checkpoint control. Cell, 82: 675-684, 1995.
11. Parsons, R., Li, G.-M., Longley, M. J., Fang, W.-H., Papadopoulos, N., Jen, J., de la Chapelle, A., Kinzler, K. W., Vogelstein B., and Modrich, P. Hypermutability and mismatch repair deficiency in RER + tumor cells. Cell, 75: 1227-1236, 1993.
12. Capecchi, M. R. Targeted gene replacement. Sci. Am., 270: 52-59, 1994.
13. Rayssiguier, C., Thaler, D. S., and Radman, M. The barrier to recombination between Escherichia coli and Salmonella typhimurium is disrupted in mismatch repair mutants. Nature (Lond.), 342: 396-401, 1989.
14. de Wind, N., Dekker, M., Berns, A., Radman, M., and te Riele, H. Inactivation of the mouse MSH2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell, 82: 321-300, 1995.
15. Shirasawa, S., Furuse, M., Yokoyama, N., and Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (Washington DC), 260: 85-88, 1993.
16. Hanson, K. D.,and Sedivy, J. M. Analysis of biological selections for high-efficiency gene targeting. Mol. Cell. Biol., 75: 45-51, 1995.
17. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
18. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
19. El-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E. Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kastan, M. E., Kohn, K. E., Elledge, S. J., Kinzler, K. W., and Vogelstein, B. WAF1/CIP1 is induced in p53-mediated Gj arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
20. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
21. Dulic, V., Kaufmann, W. K., Wilson, S. J., TTsty, T. D., Lees, E., Harper, J. W., EUedge, S. J., and Reed, S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G, arrest. Cell, 76: 1013-1023, 1994.
22. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
23. Stewart, N., Hicks, G. G., Paraskevas, F., and Mowat, M. Evidence for a second cell cycle block at G2/M by p53. Oncogene, 10: 109-1166, 1995.
24. Aloni-Grinstein, R., Schwartz, D., and Rotter, V. Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. EMBO J., 14: 1392-1401, 1995.
25. Cox, L. S., and Lane, D. P. Tumour suppressors, kinases and clamps-how p53 regulates the cell cycle in response to DNA damage. Bioessays, 17: 501-508, 1995.
26. Haffner, R., and Oren, M. Biochemical properties and biological effects of p53. Curr. Opin. Gen. & Dev., 5: 84-90, 1995.
27. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
28. Lowe, S. W., Schmitt, S. W., Smith, B. A., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849,1993.
29. Lotem, J., and Sachs, L. Hematopoetic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood, 82:1092-1095,1993.
30. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Jr., and Butel, J. S. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (Lond.), 356: 215-221, 1992.
31. Jacks, T., Remington, L, Williams, B. O., Schmitt, E. M., Halachmi, S., Branson, R. T., and Weinberg, R. A. Tumor spectrum analysis in p53 mutant mice. Curr. Biol., 4: 1-7,1994.
32. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J., Jr., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., Friend, S. H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
33. Srivastava, S., Zou, Z. Q., Pirollo, K., Blattner, W., and Chang, E. H. Germ line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature (Lond.), 348: 747-749, 1990.
34. Reynisdottir, I., Polyak, K., Iavarone, A., and Massague, J. Kip/Cip and INK4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF- β. Genes & Dev., 9: 1831-1845, 1995.
35. El-Deiry, W. S., Tokino, T., Waldman, T., Oliner, J. D., Velculescu, V. E., Burrell, M., Hill, D. E., Healy, E., Rees, J. L., Hamilton, S. R., Kinzler, K. W., and Vogelstein, B. Topological control of p2iWAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55: 2910-2919, 1995.
36. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H., and Reid, B. J. A p53-dependent mouse spindle checkpoint. Science (Washington, D.C.), 267: 1353-1356, 1995.